The enrollment milestone removes a key timeline risk for the TEBE-AM readout. Monitor for topline OS data expected by end of 2026, a positive result could significantly expand KIMMTRAK's addressable market beyond uveal melanoma into the larger cutaneous melanoma setting.
Drug in focus
IMCR drug pipeline →KIMMTRAK
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.
- Next catalyst
- None dated
What to watchThe key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $32.46entry
- T+1 · 2mo ago −2.11%α −1.65% · $31.78
- T+5 · 8w ago −0.86%α −0.97% · $32.18
- T+20 · 5w ago −10.54%α −12.80% · $29.04
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM registrational trial evaluating tebentafusp (KIMMTRAK) in previously treated advanced melanoma. Topline overall survival data is expected as early as end of 2026. This is a positive clinical milestone that de-risks the trial timeline but provides no efficacy data yet.
Key Facts
- Target enrollment of 540 patients achieved in Phase 3 TEBE-AM trial of tebentafusp in previously treated advanced melanoma
- Topline overall survival data expected as early as end of 2026
- Trial evaluates tebentafusp as monotherapy and in combination with pembrolizumab vs investigator's choice
- Primary endpoint is overall survival
- Company estimates up to 4,000 HLA-A*02:01-positive patients in the US and Europe with this indication
Financial Impact
No financial data in filing; clinical milestone de-risks a potential label expansion opportunity for KIMMTRAK into a larger melanoma market (cutaneous vs current uveal melanoma indication)
Risk Factors
- No efficacy data yet, OS results may fail to meet statistical significance
- Competition from existing PD-1 and BRAF-targeted therapies in post-PD1 advanced melanoma
- KIMMTRAK carries a boxed warning for Cytokine Release Syndrome which may limit adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001671927-26-000026 |
| Document: pressrelease-tebexamenroll.htm | 0001671927-26-000026 |
| Document: 0001671927-26-000026-index-headers.html | 0001671927-26-000026 |
| Document: 0001671927-26-000026-index.html | 0001671927-26-000026 |
| Document: 0001671927-26-000026.txt | 0001671927-26-000026 |
Track record
14 reports on IMCR
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
- Sep 14, 20269w ago 8-K Bullish 6/10 Viewing Entry $32.46 Now $28.88 −11.03% settles Dec 8
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
- May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers